enter passkey to continue
incorrect passkey
Original Genomics bridges the gap between genomic research and clinical practice, transforming variant-level discoveries into actionable care pathways that reach patients when they need them most.
Genomic discoveries take an average of 17 years to move from publication to clinical practice. For the 30 million Americans living with rare diseases, this delay translates into diagnostic odysseys averaging 5 to 7 years, cycling through 7 or more specialists, and accumulating hundreds of thousands of dollars in low-value care that a single genetic test could have rendered unnecessary.
The gap is not a failure of science. The discoveries exist. The tests are validated. The evidence is published. What is missing is the infrastructure to move findings from journals into care delivery systems at the speed patients deserve.
The gap is closing. Advances in rapid genome sequencing, variant curation pipelines, and evidence-based clinical pathways are compressing the translation timeline from decades to months in the highest-acuity settings.
Novel pathogenic variants identified in research
Systematic review and clinical validity assessment
Clinical practice guidelines and testing criteria
Diagnosis changes management and improves outcomes
Testing reaches patients through structured care pathways
Original Genomics operates across the full spectrum of genomic translation, from rare disease diagnosis to population-scale implementation.
Structured diagnostic pathways across 20 organ systems with documented yields reaching 95%. Ending the diagnostic odyssey through systematic, evidence-based genetic testing programs.
Translating genotype-drug interaction data into prescribing workflows. Preemptive pharmacogenomic panels prevent adverse drug events and optimize therapeutic selection across clinical settings.
Large-scale genomic data informing public health strategies, carrier screening programs, and population-level risk stratification. Turning biobank-scale data into community-level health interventions.
Genomics-informed trial design accelerates therapeutic development. Molecular stratification improves enrollment precision, reduces trial failure rates, and connects patients with targeted therapies faster.
Our evidence framework is built on 80+ peer-reviewed references spanning 20 organ systems, organized into a transparent tiered structure that distinguishes strong evidence from emerging data.
Published diagnostic yield data, 3+ references, defined ES/GS indications.
Published data with narrower evidence base or highly variable yields.
Yield depends heavily on indication specificity. Disorders of sex development achieve 60% diagnostic yield, while idiopathic infertility remains at 1.5%. These systems represent growth areas where the evidence is actively expanding.
Rapid sequencing in critical care delivers the highest-impact translation.
Rapid genome sequencing in critically ill neonates achieves 25% reduction in length of stay. In PICU/CICU settings, 80% of diagnoses change clinical management. Median turnaround times of 3 to 9 days make this the most compelling example of genomic translation in practice.
Original Genomics supports every stage of the pipeline from genomic discovery to patient benefit, compressing decades of translation into structured, measurable pathways.
Novel variant identification through research sequencing and large-scale genomic studies
Systematic evidence review, variant classification, and clinical validity assessment per ACMG standards
Embedding actionable findings into clinical pathways, testing panels, and decision-support systems
Structured care pathways bring validated genomic testing to patients through health systems and payer programs
The translational pipeline is not linear or slow by necessity. With the right infrastructure, genomic discoveries reach patients in months, not decades. Original Genomics exists to build and support that infrastructure across every organ system where genetic testing has demonstrated clinical utility.